Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 82 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Herman AO. FDA approves new cholesterol-lowering drug. Journal Watch 2020:24 de febrero. [Ref.ID 103538]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
3. Cita con resumen
McGettigan P, Ferner RE. PCSK9 inhibitors for hypercholesterolaemia. BMJ 2017;356:j188. [Ref.ID 101397]
4. Cita con resumen
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Unqi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAVOV randomized clinical trial. JAMA 2016;316:2373-84. [Ref.ID 101030]
5. Cita con resumen
Pintó X, García Gómez MC. Nuevos tratamientos para la hipercolesterolemia. Med Clin (Barc) 2016;146:172-7. [Ref.ID 100102]
6. Cita con resumen
Anónimo. Two new lipid-regulating drugs. Drug Ther Bull 2016;54:18-21. [Ref.ID 100095]
7. Cita con resumen
Anónimo. Evolocumab (Repatha) - A second PCSK9 inhibitor to lower LDL-cholesterol. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:140-1. [Ref.ID 99812]
8. Cita con resumen
Anónimo. Alirocumab (Praluent) to lower LDL-cholesterol. Med Lett Drugs Ther 2015;57:113-5. [Ref.ID 99651]
9. Cita con resumen
Kesselheim AS, Laggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA 2015;314:27 de octubre. [Ref.ID 99526]
10.Enlace a cita original Cita con resumen
Goulooze SC, Cohen AF, Rissmann R. Lomitapide. Br J Clin Pharmacol 2015;80:179-81. [Ref.ID 99474]
11.Tiene citas relacionadas Cita con resumen
Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: a new era in lipid-lowering treatment?. Ann Intern Med 2015;163:64-5. [Ref.ID 99337]
12.Tiene citas relacionadas Cita con resumen
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry US, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino Sr RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ. Effect of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40-51. [Ref.ID 99336]
13. Cita con resumen
Kastelein JJP, Besseling J, Shah S, Bergeron J, Langslet G, Hovingh GK, Al-Saady N, Koeijvoets M, Hunter J, Johnson-Levonas AO, Fable J, Sapre A, Mitchel Y. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015;385:2153-61. [Ref.ID 99163]
14.Tiene citas relacionadas
Stone NJ, Lloyd-Jones DM. Lowering LDL cholesterol is good, but how and in whom?. N Engl J Med 2015;372:1564-5. [Ref.ID 99059]
15.Tiene citas relacionadas Cita con resumen
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]
16. Cita con resumen
Preiss D, Sattar N. Does the LDL receptor play a role in the risk of developing type 2 diabetes?. JAMA 2015;313:1016-7. [Ref.ID 98938]
17. Cita con resumen
Anónimo. Lomitapide. Prescrire 2015;35:168-71. [Ref.ID 98923]
18. Cita con resumen
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. [Ref.ID 98743]
19. Cita con resumen
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D, for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. [Ref.ID 98742]
20. Cita con resumen
Anónimo. Two new drugs for homozygous familial hypercholesterolemia. Med Lett Drugs Ther 2013;55:25-7. [Ref.ID 95462]
Seleccionar todas
 
 1 a 20 de 82 siguiente >>